Although there are many unanswered questions related to advanced-stage BRAFV600E melanomas, the major indecision in current practice is the choice between BRAF/MEK inhibitors or immunotherapy for metastatic or high-risk disease patients [4]. Here, BRAF is linked to melanoma.